These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27520943)

  • 21. Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.
    Yu SH; Dubey NK; Li WS; Liu MC; Chiang HS; Leu SJ; Shieh YH; Tsai FC; Deng WP
    PLoS One; 2016; 11(11):e0166342. PubMed ID: 27832180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy and endothelial dysfunction: Current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study.
    Leung WK; Gao L; Siu PM; Lai CW
    Life Sci; 2016 Dec; 166():121-130. PubMed ID: 27765534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group.
    Schmidt S; Giessel R; Bergis KH; Strojek K; Grzeszczak W; Ganten D; Ritz E
    Nephrol Dial Transplant; 1996 Sep; 11(9):1755-61. PubMed ID: 8918618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
    Remuzzi G; Macia M; Ruggenenti P
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S90-7. PubMed ID: 16565256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antihypertensive therapy in diabetes mellitus].
    Hess B
    Ther Umsch; 1999 Jan; 56(1):25-32. PubMed ID: 10067131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
    Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
    BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Risk of chronic renal failure in patients with non-insulin dependent diabetes mellitus with diabetic nephropathy and the stage of permanent proteinuria and arterial hypertension: role of clinical factors].
    Dobronravov VA
    Ter Arkh; 2000; 72(6):52-4. PubMed ID: 10900651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.
    Navarro-González JF; Muros M; Mora-Fernández C; Herrera H; Meneses B; García J
    J Diabetes Complications; 2011; 25(5):314-9. PubMed ID: 21144773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current role of renal biopsy in diabetic patients.
    Bermejo S; Pascual J; Soler MJ
    Minerva Med; 2018 Apr; 109(2):116-125. PubMed ID: 29115800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.
    Lv M; Chen Z; Hu G; Li Q
    Drug Discov Today; 2015 Mar; 20(3):332-46. PubMed ID: 25448752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetic nephropathy.
    Ritz E
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
    Chantrel F; Bouiller M; Kolb I; Hannedouche T
    Nephrologie; 2000; 21(2):47-55. PubMed ID: 10798204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Captopril reduction of albuminuria in type-II diabetics with diabetic nephropathy].
    Melchor-Ortiz JL; Wacher-Rodarte N; Halabe-Cherem J; Lifshitz-Guinzberg A
    Gac Med Mex; 1991; 127(3):261-6. PubMed ID: 1800220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does body mass index influence the decline of glomerular filtration rate in diabetic type 2 patients with diabetic nephropathy in a developing country?
    Bentata Y; Latrech H; Abouqal R
    Ren Fail; 2014 Jul; 36(6):838-46. PubMed ID: 24673339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities.
    Raval N; Kumawat A; Kalyane D; Kalia K; Tekade RK
    Drug Discov Today; 2020 May; 25(5):862-878. PubMed ID: 31981791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current issues in the diagnosis and therapy of diabetic nephropathy].
    de Châtel R; Mogyorósi A; Ziyadeh FN
    Orv Hetil; 1997 Jan; 138(4):187-93. PubMed ID: 9072751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thioredoxin-interacting protein: a potential therapeutic target for treatment of progressive fibrosis in diabetic nephropathy.
    Tan CY; Weier Q; Zhang Y; Cox AJ; Kelly DJ; Langham RG
    Nephron; 2015; 129(2):109-27. PubMed ID: 25662516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.